Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 163Carcinoma, Renal Cell 45Urinary Bladder Neoplasms 33Carcinoma, Transitional Cell 19Lung Neoplasms 14Melanoma 11Neoplasm Metastasis 10Glioma 10Breast Neoplasms 9Wilms Tumor 8Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Sarcoma 7Kidney Neoplasms 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Ureteral Neoplasms 6Testicular Neoplasms 6Rhabdoid Tumor 6Pancreatic Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Brain Neoplasms 6

Interventions

atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1GSK 1363089 1Erlotinib Hydrochloride 1Disulfides 1Contrast Media 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillary renal cell carcinoma, sporadic × Magnetic Resonance Spectroscopy × Genitourinary × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡